Top

Published in:

01-12-2020 | Ovarian Cancer | Critical Review

Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer

Authors: Paula Martin-Gonzalez, Mireia Crispin-Ortuzar, Leonardo Rundo, Maria Delgado-Ortet, Marika Reinius, Lucian Beer, Ramona Woitek, Stephan Ursprung, Helen Addley, James D. Brenton, Florian Markowetz, Evis Sala

Published in: Insights into Imaging | Issue 1/2020

Abstract

Background

Ovarian cancer survival rates have not changed in the last 20 years. The majority of cases are High-grade serous ovarian carcinomas (HGSOCs), which are typically diagnosed at an advanced stage with multiple metastatic lesions. Taking biopsies of all sites of disease is infeasible, which challenges the implementation of stratification tools based on molecular profiling.

Main body

In this review, we describe how these challenges might be overcome by integrating quantitative features extracted from medical imaging with the analysis of paired genomic profiles, a combined approach called radiogenomics, to generate virtual biopsies. Radiomic studies have been used to model different imaging phenotypes, and some radiomic signatures have been associated with paired molecular profiles to monitor spatiotemporal changes in the heterogeneity of tumours. We describe different strategies to integrate radiogenomic information in a global and local manner, the latter by targeted sampling of tumour habitats, defined as regions with distinct radiomic phenotypes.

Conclusion

Linking radiomics and biological correlates in a targeted manner could potentially improve the clinical management of ovarian cancer. Radiogenomic signatures could be used to monitor tumours during the course of therapy, offering additional information for clinical decision making. In summary, radiogenomics may pave the way to virtual biopsies and treatment monitoring tools for integrative tumour analysis.

Ovarian Cancer, Cancer UK. http://www.cancerindex.org/clink45c.htm.

Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C (2019) High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci 20:952PubMedCentralCrossRef

Kohn EC, Ivy SP (2017) Whence high-grade serous ovarian cancer. Am Soc Clin Oncol Educ Book 37:443–448 https://doi.org/10.1200/edbk_174718PubMedCrossRef

Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G (2019) Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer 11:1179299X1986081 https://doi.org/10.1177/1179299x19860815CrossRef

Bowtell DD, Böhm S, Ahmed AA et al (2015) Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15:668–679PubMedPubMedCentralCrossRef

Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C (2013) Emerging landscape of oncogenic signatures across human cancers. Nat Genet 45:1127–1133 https://doi.org/10.1038/ng.2762PubMedPubMedCentralCrossRef

Mishra S, Whetstine JR (2016) Different facets of copy number changes: permanent, transient, and adaptive. Mol Cell Biol 36:1050–1063 https://doi.org/10.1128/mcb.00652-15PubMedPubMedCentralCrossRef

Stack MS, Nephew KP, Burdette JE, K Mitra A (2018) The Tumor Microenvironment of High Grade Serous Ovarian Cancer. Cancers (Basel) 11(1):21 https://doi.org/10.3390/cancers11010021CrossRef

Labidi-Galy SI, Papp E, Hallberg D et al (2017) High grade serous ovarian carcinomas originate in the fallopian tube. Nat Commun 8:1–11 https://doi.org/10.1038/s41467-017-00962-1CrossRef

10.

Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609–615 https://doi.org/10.1038/nature10166CrossRef

11.

Hoppe MM, Sundar R, Tan DSP, Jeyasekharan AD (2018) Biomarkers for homologous recombination deficiency in cancer. J Natl Cancer Inst 110:704–713 https://doi.org/10.1093/jnci/djy085PubMedCrossRef

12.

Colombo PE, Fabbro M, Theillet C, Bibeau F, Rouanet P, Ray-Coquard I (2014) Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol 89:207–216PubMedCrossRef

13.

Alkema NG, Wisman GB, van der Zee AG, van Vugt MA, de Jong S (2016) Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: different models for different questions. Drug Resist Updat 24:55–69 https://doi.org/10.1016/j.drup.2015.11.005PubMedCrossRef

14.

Cunnea P, Stronach EA (2014) Modeling platinum sensitive and resistant high-grade serous ovarian cancer: Development and applications of experimental systems. Front Oncol 4:81PubMedPubMedCentralCrossRef

15.

Kim S, Han Y, Kim SI, Kim HS, Kim SJ, Song YS (2018) Tumor evolution and chemoresistance in ovarian cancer. NPJ Precis Oncol 2:20 https://doi.org/10.1038/s41698-018-0063-0PubMedPubMedCentralCrossRef

16.

Salomon-Perzyński A, Salomon-Perzyńska M, Michalski B, Skrzypulec-Plinta V (2017) High-grade serous ovarian cancer: the clone wars. Arch Gynecol Obstet 295:569–576PubMedPubMedCentralCrossRef

17.

Kitamura T, Qian BZ, Pollard JW (2015) Immune cell promotion of metastasis. Nat Rev Immunol 15:73–86PubMedPubMedCentralCrossRef

18.

Vaughan S, Coward JI, Bast RC Jr et al (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11:719PubMedPubMedCentralCrossRef

19.

Anderson ARA, Weaver AM, Cummings PT, Quaranta V (2006) Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 127:905–915PubMedCrossRef

20.

Maley CC, Aktipis A, Graham TA et al (2017) Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 17(10):605–661 https://doi.org/10.1038/nrc.2017.69PubMedPubMedCentralCrossRef

21.

Gerlinger M, Rowan AJ, Horswell S et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892 https://doi.org/10.1056/NEJMoa1113205PubMedPubMedCentralCrossRef

22.

Sanduleanu S, Woodruff HC, de Jong EEC et al (2018) Tracking tumor biology with radiomics: a systematic review utilizing a radiomics quality score. Radiother Oncol 127:349–360PubMedCrossRef

23.

Fotopoulou C, Hall M, Cruickshank D et al (2017) British Gynaecological Cancer Society (BGCS) Epithelial Ovarian / Fallopian Tube / Primary Peritoneal Cancer Guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol 213:123–139PubMedCrossRef

24.

SIGN 135 Management of epithelial ovarian cancer. https://www.sign.ac.uk/sign-135-management-of-epithelial-ovarian-cancer.

25.

Ovarian cancer: recognition and initial management guidance, NICE. https://www.nice.org.uk/guidance/cg122. Accessed 28 Jun 2020

26.

Larue RT, Defraene G, De Ruysscher D, Lambin P, Van Elmpt W (2017) Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures. Br J Radiol 90:20160665 https://doi.org/10.1259/bjr.20160665PubMedPubMedCentralCrossRef

27.

Aerts HJWL, Velazquez ER, Leijenaar RTH et al (2014) Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 5 https://doi.org/10.1038/ncomms5006

28.

Lambin P, Rios-Velazquez E, Leijenaar R et al (2012) Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48:441–446 https://doi.org/10.1016/j.ejca.2011.11.036PubMedPubMedCentralCrossRef

29.

Gillies RJ, Kinahan PE, Hricak H (2016) Radiomics: images are more than pictures, they are data. Radiology 278:563–577 https://doi.org/10.1148/radiol.2015151169PubMedCrossRef

30.

Lambin P, Leijenaar RTH, Deist TM et al (2017) Radiomics: The bridge between medical imaging and personalised medicine. Nat Rev Clin Oncol 14:749–762CrossRefPubMed

31.

Papanikolaou N, Matos C, Koh DM (2020) How to develop a meaningful radiomic signature for clinical use in oncologic patients. Cancer Imaging 20:33PubMedPubMedCentralCrossRef

32.

Rizzo S, Botta F, Raimondi S et al (2018) Radiomics of high-grade serous ovarian cancer: association between quantitative CT features, residual tumour and disease progression within 12 months. Eur Radiol 28:4849–4859 https://doi.org/10.1007/s00330-018-5389-zPubMedCrossRef

33.

Parekh V, Jacobs MA (2016) Radiomics: a new application from established techniques. Expert Rev Precis Med Drug Dev 1:207–226PubMedPubMedCentralCrossRef

34.

Parmar C, Grossmann P, Bussink J, Lambin P, Aerts HJ (2015) Machine learning methods for quantitative radiomic biomarkers. Sci Rep 5 https://doi.org/10.1038/srep13087

35.

Hosny A, Aerts HJ, Mak RH (2019) Handcrafted versus deep learning radiomics for prediction of cancer therapy response. Lancet Digital Health 1(3):e106–e107CrossRefPubMed

36.

Montagnon E, Cerny M, Cadrin-Chênevert A et al (2020) Deep learning workflow in radiology: a primer. Insights Imaging 11:22PubMedPubMedCentralCrossRef

37.

Vial A, Stirling D, Field M et al (2018) The role of deep learning and radiomic feature extraction in cancer-specific predictive modelling: a review. Transl Cancer Res 7:803–816 https://doi.org/10.21037/21823CrossRef

38.

Traverso A, Wee L, Dekker A, Gillies R (2018) Repeatability and reproducibility of radiomic features: a systematic review. Int J Radiat Oncol Biol Phys 102:1143–1158 https://doi.org/10.1016/j.ijrobp.2018.05.053PubMedPubMedCentralCrossRef

39.

Avanzo M, Stancanello J, El Naqa I (2017) Beyond imaging: the promise of radiomics. Phys Medica 38:122–139CrossRef

40.

Mazurowski MA (2015) Radiogenomics: what it is and why it is important. J Am Coll Radiol 12:862–866 https://doi.org/10.1016/j.jacr.2015.04.019PubMedCrossRef

41.

Tothill RW, Tinker AV, George J et al (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14:5198–5208 https://doi.org/10.1158/1078-0432.CCR-08-0196PubMedCrossRef

42.

Nougaret S, Lakhman Y, Gönen M et al (2017) High-grade serous ovarian cancer: associations between BRCA mutation status, CT imaging phenotypes, and clinical outcomes. Radiology 285:472–481 https://doi.org/10.1148/radiol.2017161697PubMedCrossRef

43.

Vargas HA, Veeraraghavan H, Micco M et al (2017) A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome. Eur Radiol 27:3991–4001 https://doi.org/10.1007/s00330-017-4779-yPubMedPubMedCentralCrossRef

44.

Vargas HA, Miccò M, Hong SI et al (2015) Association between morphologic CT imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: a hypothesis-generating study. Radiology 274:742–751 https://doi.org/10.1148/radiol.14141477PubMedCrossRef

45.

Vargas HA, Huang EP, Lakhman Y et al (2017) Radiogenomics of high-grade serous ovarian cancer: multireader multi-institutional study from the Cancer Genome Atlas Ovarian Cancer Imaging Research Group. Radiology 285:482–492 https://doi.org/10.1148/radiol.2017161870PubMedCrossRef

46.

Beer L, Sahin H, Bateman N et al (2020) Integration of proteomics with CT-based qualitative and texture features in high-grade serous ovarian cancer patients: an exploratory analysis. Eur Radiol https://doi.org/10.17863/CAM.49644

47.

Lu H, Arshad M, Thornton A et al (2019) A mathematical-descriptor of tumor-mesoscopic-structure from computed-tomography images annotates prognostic- and molecular-phenotypes of epithelial ovarian cancer. Nat Commun 10:1–11 https://doi.org/10.1038/s41467-019-08718-9CrossRef

48.

Weigelt B, Vargas HA, Selenica P et al (2019) Radiogenomics analysis of intratumor heterogeneity in a patient with high-grade serous ovarian cancer. JCO Precis Oncol:1–9 https://doi.org/10.1200/po.18.00410

49.

Liu J, Cristea MC, Frankel P et al (2012) Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet 205:34–41 https://doi.org/10.1016/j.cancergen.2012.01.008PubMedPubMedCentralCrossRef

50.

Yang D, Khan S, Sun Y et al (2011) Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306:1557–1565 https://doi.org/10.1001/jama.2011.1456PubMedPubMedCentralCrossRef

51.

Hyman DM, Zhou Q, Iasonos A et al (2012) Improved survival for BRCA2 -associated serous ovarian cancer compared with both BRCA -negative and BRCA1 -associated serous ovarian cancer. Cancer 118:3703–3709 https://doi.org/10.1002/cncr.26655PubMedCrossRef

52.

Etemadmoghadam D, Defazio A, Beroukhim R et al (2009) Integrated genome-wide DMA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 15:1417–1427 https://doi.org/10.1158/1078-0432.CCR-08-1564PubMedPubMedCentralCrossRef

53.

Hwang HC, Clurman BE (2005) Cyclin E in normal and neoplastic cell cycles. Oncogene 24:2776–2786PubMedCrossRef

54.

Weinstein JN, Collisson EA, Mills GB et al (2013) The cancer genome atlas pan-cancer analysis project. Nat Genet 45:1113–1120PubMedPubMedCentralCrossRef

55.

Verhaak RGW, Tamayo P, Yang JY et al (2013) Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 123:517–525 https://doi.org/10.1172/JCI65833PubMed

56.

Yang JY, Yoshihara K, Tanaka K et al (2013) Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 123:3740–3750 https://doi.org/10.1172/JCI68509PubMedPubMedCentral

57.

Cui Y, Ren S, Tha KK, Wu J, Shirato H, Li R (2017) Volume of high-risk intratumoural subregions at multi-parametric MR imaging predicts overall survival and complements molecular analysis of glioblastoma. Eur Radiol 27:3583–3592 https://doi.org/10.1007/s00330-017-4751-xPubMedCrossRef

58.

Li Y, Liu X, Xu K et al (2018) MRI features can predict EGFR expression in lower grade gliomas: A voxel-based radiomic analysis. Eur Radiol 28:356–362 https://doi.org/10.1007/s00330-017-4964-zPubMedCrossRef

59.

Brown R, Zlatescu M, Sijben A et al (2008) The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14:2357–2362 https://doi.org/10.1158/1078-0432.CCR-07-1964PubMedCrossRef

60.

Wu J, Sun X, Wang J et al (2017) Identifying relations between imaging phenotypes and molecular subtypes of breast cancer: Model discovery and external validation. J Magn Reson Imaging 46:1017–1027 https://doi.org/10.1002/jmri.25661PubMedPubMedCentralCrossRef

61.

Ashraf AB, Daye D, Gavenonis S et al (2014) Identification of intrinsic imaging phenotypes for breast cancer tumors: preliminary associations with gene expression Profiles. Radiology 272:374–384 https://doi.org/10.1148/radiol.14131375PubMedCrossRef

62.

Grossmann P, Stringfield O, El-Hachem N et al (2017) Defining the biological basis of radiomic phenotypes in lung cancer. Elife 6 https://doi.org/10.7554/eLife.23421

63.

Rios Velazquez E, Parmar C, Liu Y et al (2017) Somatic mutations drive distinct imaging phenotypes in lung cancer. Cancer Res 77:3922–3930 https://doi.org/10.1158/0008-5472.CAN-17-0122PubMedCrossRef

64.

Segal E, Sirlin CB, Ooi C et al (2007) Decoding global gene expression programs in liver cancer by noninvasive imaging. Nat Biotechnol 25:675–680 https://doi.org/10.1038/nbt1306PubMedCrossRef

65.

Yamamoto S, Huang D, Du L et al (2016) Radiogenomic analysis demonstrates associations between ¹⁸ F-fluoro-2-deoxyglucose PET, prognosis, and epithelial-mesenchymal transition in non–small cell lung cancer. Radiology 280:261–270 https://doi.org/10.1148/radiol.2016160259PubMedCrossRef

66.

Cottereau AS, Lanic H, Mareschal S et al (2016) Molecular profile and FDG-PET/CT Total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-Cell lymphoma. Clin Cancer Res 22:3801–3809 https://doi.org/10.1158/1078-0432.CCR-15-2825PubMedCrossRef

67.

Lo Gullo R, Daimiel I, Morris EA, Pinker K (2020) Combining molecular and imaging metrics in cancer: radiogenomics. Insights Imaging 11:1–17PubMedPubMedCentralCrossRef

68.

Sala E, Mema E, Himoto Y et al (2017) Unravelling tumour heterogeneity using next-generation imaging: radiomics, radiogenomics, and habitat imaging. Clin Radiol 72:3–10PubMedCrossRef

69.

Pinker K, Shitano F, Sala E et al (2018) Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging 47:604–620PubMedCrossRef

70.

Jamal-Hanjani M, Wilson GA, McGranahan N et al (2017) Tracking the evolution of non–small-cell lung cancer. N Engl J Med 376:2109–2121 https://doi.org/10.1056/NEJMoa1616288PubMedCrossRef

71.

Apte AP, Iyer A, Crispin-Ortuzar M et al (2018) Technical note: extension of CERR for computational radiomics: a comprehensive MATLAB platform for reproducible radiomics research. Med Phys 45:3713–3720 https://doi.org/10.1002/mp.13046CrossRef

72.

Haralick RM, Dinstein I, Shanmugam K (1973) Textural features for image classification. IEEE Trans Syst Man Cybern SMC-3:610–621 https://doi.org/10.1109/TSMC.1973.4309314CrossRef

73.

Gatenby RA, Grove O, Gillies RJ (2013) Quantitative imaging in cancer evolution and ecology. Radiology 269:8–15PubMedPubMedCentralCrossRef

74.

O'Connor JP, Rose CJ, Waterton JC, Carano RA, Parker GJ, Jackson A (2015) Imaging intratumor heterogeneity: Role in therapy response, resistance, and clinical outcome. Clin Cancer Res 21:249–257PubMedCrossRef

75.

McPherson A, Roth A, Laks E et al (2016) Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat Genet 48:758–767 https://doi.org/10.1038/ng.3573PubMedCrossRef

76.

McGarry SD, Hurrell SL, Iczkowski KA et al (2018) Radio-pathomic maps of epithelium and lumen density predict the location of high-grade prostate cancer. Int J Radiat Oncol Biol Phys 101:1179–1187 https://doi.org/10.1016/j.ijrobp.2018.04.044PubMedPubMedCentralCrossRef

77.

Hurrell SL, McGarry SD, Kaczmarowski A et al (2017) Optimized b-value selection for the discrimination of prostate cancer grades, including the cribriform pattern, using diffusion weighted imaging. J Med Imaging (Bellingham) 5:1 https://doi.org/10.1117/1.jmi.5.1.011004CrossRef

78.

Turkbey B, Mani H, Shah V et al (2011) Multiparametric 3 T prostate magnetic resonance imaging to detect cancer: Histopathological correlation using prostatectomy specimens processed in customized magnetic resonance imaging based molds. J Urol 186:1818–1824 https://doi.org/10.1016/j.juro.2011.07.013PubMedPubMedCentralCrossRef

79.

McGarry SD, Bukowy JD, Iczkowski KA et al (2019) Gleason probability maps: a radiomics tool for mapping prostate cancer likelihood in MRI space. Tomography 5:127–134 https://doi.org/10.18383/j.tom.2018.00033PubMedPubMedCentralCrossRef

80.

Trout AT, Batie MR, Gupta A, Sheridan RM, Tiao GM, Towbin AJ (2017) 3D printed pathological sectioning boxes to facilitate radiological-pathological correlation in hepatectomy cases. J Clin Pathol 70:984–987 https://doi.org/10.1136/jclinpath-2016-204293PubMedCrossRef

81.

Dwivedi DK, Chatzinoff Y, Zhang Y et al (2018) Development of a patient-specific tumor mold using magnetic resonance imaging and 3-dimensional printing technology for targeted tissue procurement and radiomics analysis of renal masses. Urology 112:209–214 https://doi.org/10.1016/j.urology.2017.08.056PubMedCrossRef

82.

Crispin-Ortuzar M, Gehrung M, Ursprung S et al (2019) 3D-printed moulds of renal tumours for image-guided tissue sampling in the clinical setting. bioRxiv:658831 https://doi.org/10.1101/658831

83.

Stoyanova R, Pollack A, Takhar M et al (2016) Association of multiparametric MRI quantitative imaging features with prostate cancer gene expression in MRI-targeted prostate biopsies. Oncotarget 7:53362–53376 https://doi.org/10.18632/oncotarget.10523PubMedPubMedCentralCrossRef

84.

Rizzo S, Botta F, Raimondi S et al (2018) Radiomics: the facts and the challenges of image analysis. Eur Radiol Exp 2:36PubMedPubMedCentralCrossRef

85.

Buckler AJ, Bresolin L, Dunnick NR, Sullivan DC (2011) A collaborative enterprise for multi-stakeholder participation in the advancement of quantitative imaging. Radiology 258:906–914 https://doi.org/10.1148/radiol.10100799PubMedCrossRef

86.

Meyer M, Ronald J, Vernuccio F et al (2019) Reproducibility of CT radiomic features within the same patient: influence of radiation dose and CT reconstruction settings. Radiology 293:583–591 https://doi.org/10.1148/radiol.2019190928PubMedCrossRef

Title: Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer
Authors: Paula Martin-Gonzalez
Mireia Crispin-Ortuzar
Leonardo Rundo
Maria Delgado-Ortet
Marika Reinius
Lucian Beer
Ramona Woitek
Stephan Ursprung
Helen Addley
James D. Brenton
Florian Markowetz
Evis Sala
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Ovarian Cancer
Ovarian Cancer
Published in: Insights into Imaging / Issue 1/2020
Electronic ISSN: 1869-4101
DOI: https://doi.org/10.1186/s13244-020-00895-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer

Abstract

Background

Main body

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Main body

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Traumatic and non-traumatic bone marrow edema in ankle MRI: a pictorial essay

Imaging spectrum of abnormal subcutaneous and visceral fat distribution

Radiology artificial intelligence, a systematic evaluation of methods (RAISE): a systematic review protocol

Vascular lesions of the head and neck: an update on classification and imaging review

European Society of Emergency Radiology: guideline on radiological polytrauma imaging and service (short version)

Feasibility of a paediatric radiology escape room for undergraduate education